Key Highlights
- Halda Therapeutics raises $126M in Series B extension, total $202M funding to date.
- Proceeds will advance two RIPTAC candidates into clinical trials for prostate and breast cancer.
- Lead candidate HLD-0915 set to enter Phase 1 trial in 2025 for metastatic, castration-resistant prostate cancer (mCRPC).
- New funding supports development of RIPTAC platform and team expansion.
Source: Business Wire
Notable Quotes
- “This financing will enable us to bring to patients our oral, selective, and widely applicable cancer cell-killing mechanism that is designed to overcome drug resistance.” — Kat Kayser-Bricker, PhD, Chief Scientific Officer at Halda Therapeutics
- “RIPTAC therapies offer an ability to selectively kill cancer cells based on differential protein expression in orally bioavailable medicines.” — Joe Cabral, Principal at Frazier Life Sciences
- “Halda’s lead RIPTAC candidate, HLD‑0915, offers the potential for a mutation-agnostic small molecule approach in the mCRPC setting.” — Arjun Goyal, MD, Co-Founder and Managing Director at Vida Ventures
SoHC's Take
Halda Therapeutics’ successful Series B extension underscores the strong investor confidence in its innovative RIPTAC platform, which represents a significant advancement in the fight against cancer. The ability of RIPTAC therapeutics to address drug resistance—a major challenge in oncology—positions Halda as a potential leader in next-generation cancer treatments. As the company moves forward with clinical trials, particularly for challenging metastatic cases in prostate and breast cancer, its progress will be closely watched by both the biotech industry and the broader medical community.
